Oncology News

SHANGHAI & SUZHOU, China--(BUSINESS WIRE)--Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced that preclinical data from its IL-15 and IL-18 programs will be presented at the 2026 AACR Annual Meeting held April 17-22, 2026 in San Diego, California. IL-15 Programs: FL115 is an engineered IL-15/IL15Rα-Fbody fusion protein and has demonstrated best-in-class (BIC) profile as monothera...

WASHINGTON--(BUSINESS WIRE)--The global nonprofit organization Cancer Support Community (CSC), together with its network of CSC, Gilda’s Club locations, and healthcare partner sites, is taking over one of music's most unforgettable phone numbers. Effective today, anyone impacted by cancer can call CSC-867-5309 (272-867-5309) to receive immediate support, trusted information, and personalized guidance from trained specialists. Sally Werner, CEO of Cancer Support Community, said: "Our Helpline re...

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of the leading AI foundation model for tumor and the immune biology, today announced it has been honored as the Innovator of the Year at the 2025 Life Sciences Times Vanguard Awards. This award recognizes the company's integrated cancer and immune system foundation models, purpose-built to accelerate oncology drug development. This recognition validates BostonGene’s success in addressing the industry’s critical challenge: the profound ineff...

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that James F. Cleary will retire as Executive Vice President and Chief Financial Officer effective June 30, 2026. Cencora has engaged an executive search firm to identify and evaluate potential successors from internal and external candidates. Mr. Cleary will assist in the search process and will serve in an advisory capacity through the end of 2026 to help ensure a smooth transition. Mr. Cleary, 62, has served as Cen...

LEHIGH VALLEY, Pa.--(BUSINESS WIRE)--The Lehigh Valley Auto Show showcases innovation, creativity, and automotive excellence, drawing car enthusiasts from across the region. This year, it will also put men’s health in the spotlight with free prostate cancer screening and education from Man Cave Health, in partnership with Pocono Raceway and the Prostate Cancer Foundation. Prostate cancer is the most common cancer in men, and screening starts with a simple PSA blood test. The coalition’s partner...

MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience, a clinical-stage biotechnology company advancing molecularly targeted intraoperative imaging, today announced the initiation of VISUALIZE 2, a Phase 3, multi-center, pivotal study to confirm the safety and efficacy of abenacianine to visualize tumors during lung cancer surgery. Abenacianine is an investigational tumor-activated, intraoperative imaging agent designed to illuminate malignant tissue in patients undergoing surgery for suspected or c...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Blood Cancer United® (formerly The Leukemia & Lymphoma Society), the largest global nonprofit focused on blood cancer patient support, research, and advocacy, today announced a strategic collaboration to develop a comprehensive, patient-centered, real-world registry for pediatric acute myeloid leukemia (pAML), a rare and aggressive blood cancer. Part of...

COLLEGE PARK, Md.--(BUSINESS WIRE)--HOHCells launches FreezOpt™, enabling controlled ice nucleation to improve cryopreservation reliability for stem cells, organoids, and cell therapy....

SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies' new patient case study demonstrates the benefit of CyPath Lung in physician decision-making and patient outcome....

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the National Comprehensive Cancer Network (NCCN®) has updated its 2026 NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer to include ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary-only diseas...